The RIVER trial is the largest study assessing the efficacy and safety of the anticoagulant rivaroxaban in patients with an artificial mitral valve to correct an irregular heart rhythm. Researchers concluded that rivaroxaban worked as well as the standard anticoagulant medication warfarin.